Apium, the innovative professional 3D printing company from Germany, is the pioneer and one of the world leaders in processing speciality polymers.
The company's activities focus on the key industrial 3D printing trends, high-performance polymers, metals and medical 3D printing.
Apium is a technology leader in PEEK 3D printing and the first company worldwide to make 3D printing of longterm implantable PEEK medical devices commercially available. The company's design and development activities have resulted in advanced products and improvement in time-to-market for medical devices.
Apium's engineers have developed a professional material extrusion 3D printing technology, which enables the 3D printing of medical-grade PEEK, without affecting its biocompatibility and sterilisation properties.
The best-in-class temperature management system of the Apium M220 3D printer enables temperature regulation in the processing of the 3D-printed medical devices for the best possible results, and together with the integrated filtration system, prevents contamination of the printed part.
The medical-grade PEEK filament processed by Apium's M220 3D printer is developed from the VESTAKEEP i4 resin by the speciality chemical producer Evonik.
The 3D printing of this medical-grade PEEK, using Apium M220 3D printers, meets the biocompatibility criteria required to produce medical implants and devices in the areas of craniomaxillofacial and hand.
This new production technology is guaranteed to reduce lead times and the cost of implant manufacturing. With medical-grade 3D printing, production can now be performed on-site in hospitals, and medical devices can be supplied with shorter lead times, saving patients' lives in time-critical surgeries.
The additive manufacturing device Apium M220 is not covered by the guidelines on medical devices. However, it is suitable for clean rooms and for the production of medical devices. The necessary certificates of biocompatibility for material and machine can be provided upon request and are included in the delivery of the product.
Some of the statements and claims in this article may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Actual results or developments may vary depending on changes in the operating environment.
Neither Apium Additive Technologies nor Evonik Resource Efficiency assume an obligation to update the forecasts, expectations or statements contained in this article.
